FAM171A1

Across TCGA pan-cancer cohorts, FAM171A1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM171A1 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM171A1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FAM171A1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where FAM171A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.823	1.000	.007	32	view →
CCRCC	DFS	Median	All	0.871	0.603	.006	23	view →
LSCC	DFS	Median	All	0.568	0.936	.045	2	view →
PDAC	DFS	Median	III,IV	0.488	0.222	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM171A1–LUAD (OS)

Open the LUAD breakdown →